PD-L1 in specimen
Jump to navigation
Jump to search
Indications
- predictive biomarker for checkpoint immunotherapy in NSCLC[1] & other malignancies[2]
Procedure
- PD-L1 testing by immunohistochemistry
More general terms
More specific terms
Additional terms
References
- ↑ Jump up to: 1.0 1.1 Fuerst ML with critique by Bowman AI Blood Test Appears to Enable Immunotherapy Selection, Monitoring - Allows repeat testing, timely monitoring, and has potential to improve adherence to NCCN guidelines. MedPage Today. ASCO Reading Room 05.31.2018 https://www.medpagetoday.com/reading-room/asco/immunotherapy/73187
- ↑ Jump up to: 2.0 2.1 Bajorin DF, Witjes JA, Gschwend JE Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 2021; 384:2102-2114. June 3 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34077643 https://www.nejm.org/doi/full/10.1056/NEJMoa2034442
- ↑ ARUP Consult: PD-L1 Testing The Physician's Guide to Laboratory Test Selection & Interpretation https://arupconsult.com/content/pd-l1-testing
PD-L1 Testing Algorithm https://arupconsult.com/algorithm/pd-l1-testing-algorithm